LouisBChaykinMD

Endocrinology • Sarasota, FL

Diabetes

Physician

Join to view full profile

Dr. Chaykin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chaykin's full profile

Already have an account?

Office
1900 Brother Geenen Way
Sarasota, FL 34236
Phone+1 941-556-3220

Fax+1 941-955-8214

Education & Training

University of Pennsylvania Health SystemResidency, Internal Medicine, 1964 - 1965
University of Pennsylvania Health SystemResidency, Internal Medicine, 1962 - 1964
Mercy Catholic Medical CenterInternship, Transitional Year, 1961 - 1962
Lewis Katz School of Medicine at Temple UniversityClass of 1961

Certifications & Licensure

PA State Medical License 1962 - Present
FL State Medical License 1973 - 2025
TN State Medical License 1981 - 1995
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals. Start of enrollment: 2008 Aug 01
Terminated
Phase 2
The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN) Start of enrollment: 2013 Nov 01
Unknown status
Not Applicable
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
Completed
Phase 2
12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
Completed
Phase 3
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM Start of enrollment: 2015 Oct 01
Completed
Phase 2
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Start of enrollment: 2016 Dec 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

16 citations
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the S...
Vanita R. Aroda, Matthew Capehorn, Louis Chaykin, Juan P. Frias, Nanna L. Lausvig
Diabetes, Obesity & Metabolism. 2020-03-01
1 citations
Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patient...
Mark Warren, Meryl Brod, Jonas Håkan-Bloch, Thomas Sparre, Louis Chaykin
Current Medical Research and Opinion. 2019-05-21
2 citations
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.
Louis B. Chaykin, Anuj Bhargava, Raymond de la Rosa, Carol Wysham, Lone Nørgård Troelsen
Clinical Diabetes. 2019-01-01